IMMUNOTHERAPY

Rescuing imperfect antigens for immuno-oncology

Article metrics

Targeting two antigens with BiTE-secreting CAR-T cells limits tumor immune escape in glioblastoma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: CART-BiTE cells target two antigens, EGFRvIII and wt EGFR, on GBM tumor cells.

References

  1. 1.

    Choi, B.D. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0192-1 (2019).

  2. 2.

    Fecci, P. E., Heimberger, A. B. & Sampson, J. H. Clin. Cancer Res. 20, 5620–5629 (2014).

  3. 3.

    Hodges, T. R. et al. Neuro-oncol. 19, 1047–1057 (2017).

  4. 4.

    Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. Clin. Cancer Res. 24, 3792–3802 (2018).

  5. 5.

    Wikstrand, C. J., McLendon, R. E., Friedman, A. H. & Bigner, D. D. Cancer Res. 57, 4130–4140 (1997).

  6. 6.

    Verhaak, R. G. et al. Cancer Cell 17, 98–110 (2010).

  7. 7.

    O’Rourke, D.M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).

  8. 8.

    Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Blood 123, 2625–2635 (2014).

  9. 9.

    Suryadevara, C. M. et al. Oncoimmunology 4, e1008339 (2015).

  10. 10.

    Chow, V. A., Shadman, M. & Gopal, A. K. Blood 132, 777–781 (2018).

Download references

Author information

Correspondence to Peter E. Fecci.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark